University of Kabianga Repository

Serum adiponectin in HIV-1 and hepatitis C virus mono- and co infected Kenyan injection drug users

Show simple item record

dc.contributor.author Ndombi, Eric M
dc.contributor.author Budambula, Valentine
dc.contributor.author Webale, Mark K
dc.contributor.author Musumba, Francis O
dc.contributor.author Wesongah, Jesca O
dc.contributor.author Mibei, Erick
dc.contributor.author Ahmed, Aabid A
dc.contributor.author Lihana, Raphael
dc.date.accessioned 2023-05-25T08:25:23Z
dc.date.available 2023-05-25T08:25:23Z
dc.date.issued 2015
dc.identifier.citation Ndombi, E. M., Budambula, V., Webale, M. K., Musumba, F. O., Wesongah, J. O., Mibei, E., ... & Were, T. (2015). Serum adiponectin in HIV-1 and hepatitis C virus mono-and co-infected Kenyan injection drug users. Endocrine Connections, 4(4), 223. en_US
dc.identifier.uri : 10.1530/EC-15-0071
dc.identifier.uri http://ir-library.kabianga.ac.ke/handle/123456789/553
dc.description Article Research on Serum adiponectin in HIV-1 and hepatitis C virus mono- and co infected Kenyan injection drug users en_US
dc.description.abstract Adiponectin is an important marker of anthropometric profiles of adipose tissue. However, association of adiponectin and adiposity in HIV mono- and co-infected and hepatitis (HCV) injection drug users (IDUs) has not been elucidated. Therefore, the relationship of total adiponectin levels with anthropometric indices of adiposity was examined in HIV mono infected (anti-retroviral treatment, ART-naive, nZ16 and -experienced, nZ34); HCV mono infected, nZ36; HIV and HCV co-infected (ART-naive, nZ5 and -experienced, nZ13); uninfected, nZ19 IDUs; and healthy controls, nZ16 from coastal Kenya. Anthropometric indices of adiposity were recorded and total circulating adiponectin levels were measured in serum samples using enzyme-linked immunosorbent assay. Adiponectin levels differed significantly amongst the study groups (P!0.0001). Post-hoc analyses revealed decreased levels in HIV mono-infected ART-naive IDUs in comparison to uninfected IDUs (P!0.05) and healthy controls (P!0.05). However, adiponectin levels were elevated in HCV mono-infected IDUs relative to HIV mono-infected ART-naive (P!0.001) and -experienced (P!0.001) as well as HIV and HCV co-infected ART-naive (P!0.05) IDUs. Furthermore, adiponectin correlated with weight (rZ0.687; PZ0.003) and BMI (rZ0.598; PZ0.014) in HIV mono-infected ART-naive IDUs; waist circumference (rZK0.626; P!0.0001), hip (rZK0.561; PZ0.001) circumference, and bust-to-waist ratio (rZ0.561; PZ0.001) in HIV mono-infected ART experienced IDUs; waist girth (rZ0.375; PZ0.024) in HCV mono-infected IDUs; and waist to-hip ratio (rZK0.872; PZ0.048) in HIV and HCV co-infected ART-naive IDUs. Altogether, these results suggest suppression of adiponectin production in treatment-naive HIV mono infected IDUs and that circulating adiponectin is a useful surrogate marker of altered adiposity in treatment-naive and -experienced HIV and HCV mono- and co-infected IDUs. en_US
dc.language.iso en en_US
dc.publisher Endocrine Connections en_US
dc.subject Adiponectin en_US
dc.subject Anthropometric markers of adiposity en_US
dc.subject Hepatitis C virus en_US
dc.subject HIV en_US
dc.subject Anti-retroviral treatment en_US
dc.subject Injection drug users en_US
dc.title Serum adiponectin in HIV-1 and hepatitis C virus mono- and co infected Kenyan injection drug users en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account